Amgen (AMGN) Q2 2010 Earnings Call July 29, 2010 5:00 pm ET Executives Arvind Sood - Vice President of Investor Relations Michael Kelly - Acting Chief Financial Officer Roger Perlmutter - Executive Vice President of Research & Development James Daly - Kevin Sharer - Chairman of the Board, Chief Executive Officer, Chairman of Executive Committee and Member of Equity Award Committee Robert Bradway - President and Chief Operating Officer Analysts Geoffrey Porges - Bernstein Research Joel Sendek - Lazard Capital Markets LLC Jim Birchenough - Barclays Capital Ian Somaiya - Piper Jaffray Companies Joshua Schimmer - Leerink Swann LLC Yaron Werber - Citigroup Inc Jason Zhang - BMO Capital Markets U.S. Michael Yee - RBC Capital Markets Corporation Mark Schoenebaum - ISI Group Inc. Eun Yang - Jefferies & Company, Inc. Eric Schmidt - Cowen and Company, LLC Rachel McMinn - BofA Merrill Lynch Geoffrey Meacham - JP Morgan Chase & Co PresentationOperator
My name is Christian, and I will be your conference facilitator today for Amgen's Second Quarter 2010 Financial Results Conference Call. [Operator Instructions] I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin. Arvind Sood Thank you, Christian, good afternoon, everybody. I would like to welcome you to our second quarterly results conference call, another solid quarter behind us as we embark on the second half of this year. It's also been a year of tremendous change as many of the uncertainties weighing on our business have now been resolved. To discuss these issues in greater detail, as well as to introduce the many changes we have had on our leadership team, I'm joined today by our Chairman and CEO, Kevin Sharer. Following Kevin, our acting CFO, Michael Kelly, will both provide additional details on our second quarter financial performance. Bob Bradway, our newly appointed President and Chief Operating Officer, will then articulate his charter for our company's operations, followed by Jim Daly. Jim is our Senior Vice President of North American Commercial Operations, and he will focus on three main topics: First, our product performance during the quarter; second, an early read on the Prolia launch; and lastly, our perspective on the recent final rule for the bundled-payment system for dialysis patients. Our Head of R&D, Roger Perlmutter will conclude our prepared comments by providing an R&D update.